Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: Selective COX-2 inhibitors and beyond

Acta Biomedica de l'Ateneo Parmense

Volumn 78, Issue 2, 2007, Pages

  Coruzzi, Gabriella ^a,b   Venturi, Nicola ^a   Spaggiari, Silvana ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b Section of Pharmacology   (Italy)

Author keywords

Cyclooxygenase; Gastrointestinal damage; Lipooxygenase; Lipoxins; Nitric oxide; Nonsteroidal antiinflammatory drugs

Indexed keywords

ALGIX; ARTILOG; ARTRID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; LEUKOTRIENE; LIPOXIN; LIPOXYGENASE INHIBITOR; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; ROFECOXIB; SOLEXA; TAUXIB; UNCLASSIFIED DRUG; VALDECOXIB;

DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE INJURY; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; INTESTINE ULCER; PHYSICAL CHEMISTRY; REVIEW; STOMACH MUCOSA;

ACETIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; COLON; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; GASTRIC MUCOSA; GASTROINTESTINAL TRACT; HUMANS; HYDROGEN SULFIDE; LIPOXINS; LIPOXYGENASE INHIBITORS; NITRIC OXIDE; NITRIC OXIDE DONORS; PROTEIN ISOFORMS; PYRROLES; SAFETY;

EID: 36249028817     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Whittle BJR. Gastrointestinal effects of nonsteroidal antiinflammatory drugs. Fundam Clin Pharmacol 2003; 17: 301-13.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5.
3. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal antiinflammatory drugs (NSAIDs). Am J Med 1999; 107: 27S-35S.
4. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
5. Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory drugs. Am J Med 1998; 104: 2S-8S.
6. Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307-14.
7. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
8. Micklewright R, Lane S, Linley W, McQuade C, Thompson F, Maskrey N. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 2003; 17: 321-32.
9. Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors-a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997; 11: 227-36.
10. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 4-13.
11. Whittle BJ. COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors Gut 2000; 47: 320-5.
12. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
13. Gudis K, Sakamoto C. The role of cyclooxygenase in gastric mucosal protection. Dig Dis Sci 2005; 50: S16-23.
14. Coruzzi G, Menozzi A, Dobrilla G. Novel non-steroidal antiinflammatory drugs: what we have learned from animal studies. Curr Drug Targets Inflamm Allergy 2004; 3: 43-61.
15. Wallace JL. COX-2: a pivotal enzyme in mucosal protection and resolution of inflammation. Scientific World Journal 2006; 6: 577-88.
16. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
17. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352: 1081-91.
18. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80.
19. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? Br Med J 2007; 334: 120-3.
20. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediator 2007; 82: 85-94.
21. Cairns JA. The coxibs and traditional nonsteroidal antiinflammatory drugs: a current perspective on cardiovascular risks. Can J Cardiol 2007; 23: 125-31.
22. Spalding WM, Reeves MJ, Whelton A. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal antiinflammatory drugs. Am J Ther 2007; 14: 3-12.
23. Atay S, Tarnawski AS, Dubois A. Eicosanoids and the stomach. Prostaglandins Other Lipid Mediator 2000; 61: 105-24.
24. Celotti F, Laufer S. Antiinflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001; 43: 429-36.
25. Fiorucci S, Meli R, Bucci M, Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in antiinflammatory therapy? Biochem Pharmacol 2001; 62: 1433-8.
26. de Leval X, Julemont F, Delarge J, Pirotte B, Dogné JM. New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9: 941-62.
27. Julémont F, Dogné JM, Pirotte B, de Leval X. Recent development in the field of dual COX / 5-LOX inhibitors. Mini Rev Med Chem 2004; 4: 633-8.
28. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of antiinflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006; 5: 91-106.
29. Wallace JL, de Lima OM Jr, Fiorucci S. Lipoxins in gastric mucosal health and disease. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 251-5.
30. Goldstein JL. Challenges in managing NSAID-associated gastrointestinal tract injury. Digestion 2004; 69 (Suppl 1): 25-33.
31. Whittle BJ. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer antiinflammatory drugs. Curr Opin Pharmacol 2004; 4: 538-45.
32. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
33. Wallace JL, Miller MJS. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology 2000; 119: 512-20.
34. Wallace JL, Cirino G. The development of gastrointestinalsparing nonsteroidal antiinflammatory drugs. Trends Pharmacol Sci 1994; 15: 405-6.
35. Wallace JL, Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003; 17: 11-20.
36. Del Soldato P, Sorrentino R, Pinto A. NO-aspirins: a class of new antiinflammatory and antithrombotic agents. Trends Pharmacol Sci 1999; 20: 319-23.
37. Hoogstraate J, Andersson LI, Berge OG, Jonzon B, Ojteg G. COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology 2003; 11: 423-8.
38. Fiorucci S, Distrutti E, Cirino G, Wallace JL. The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology 2006; 131: 259-71.
39. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S. Gastrointestinal safety and antiinflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007; 132: 261-71.
40. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000; 49: 367-92.
41. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003; 2: 879-90.
42. Zarraga IG, Schwarz ER. Coxibs and heart disease: what we have learned and what else we need to know. J Am Coll Cardiol 2007; 49: 1-14.
43. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and nonselective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81.
44. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272-7.
45. Hinz B, Brune K. Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol 2004; 16: 628-33.
46. Rainsford, KD. The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol Paris 2001; 95: 11-9.
47. Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulphonamide COX-2 inhibitors and NSAIDs. Atherosclerosis 2004; 177: 235-43.
48. Savage R. Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? Drugs Aging 2005; 22: 185-200.
49. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzene sulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-65.
50. Prasit P, Wang Z, Brideau C, et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999; 9: 1773-8.
51. Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl] - benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43: 775-7.
52. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Tiber 2001; 296: 558-66.
53. Esser R, Berry C, Du Z, Dawson J, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 2005; 144: 538-50.
54. Padi SSV, Jain NK, Singh S, Kulkarni SK. Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol 2004; 491: 69-76.
55. Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep 2003; 5: 453-8.
56. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroentenlogy 1997; 112: 387-97.
57. Iseki S. Immunocytochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach. Histochem J 1995; 27: 323-8.
58. Kargman S, Charleson S, Cartwright M, et al. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111: 445-54.
59. Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S. Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. Am J Physiol 1998; 275: G1137-45.
60. Zimmermann KC, Sarbia M, Schror K, Weber AA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998; 54: 536-40.
61. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92.
62. Wallace JL, Mcknight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119: 706-14.
63. Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 762-70.
64. To KF, Chan FK, Cheng AS, Lee TL, Ng YP, Sung JJ. Upregulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther 2001; 15: 25-34.
65. Davies NM, Sharkey KA, Asfaha S, Macnaughton WK, Wallace JL. Aspirin causes rapid up-regulation of cyclooxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther 1997; 11: 1101-8.
66. Peskar BM. Role of cyclooxygenase isoforms in gastric mucosal defence. J Physiol Paris 2001; 95: 3-9.
67. Gretzer B, Maricic N, Respondek M, Schuligoi R, Peskar BM. Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol'2001; 132: 1565-73.
68. Tsuji S, Sun WH, Tsujii M, et al. Lansoprazole induces mucosal protection through gastrin receptor-dependent upregulation of cyclooxygenase-2 in rats. J Pharmacol Exp Ther 2002; 303: 1301-8.
69. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroentenlogy 1999; 116: 1319-29.
70. Konturek PC, Brzozowski T, Pierzchalski P, et al. Activation of genes for spasmolytic peptide, transforming growth factor alpha and for cyclooxygenase (COX)-1 and COX-2 during gastric adaptation to aspirin damage in tats. Aliment Pharmacol Ther 1998; 12: 767-77.
71. 2. Dig Dis Sci 2007; 52: 478-87.
72. Schmassmann A, Peskar B, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats. Br. J. Pharmacol 1998; 123: 795-804.
73. Yamamoto H, Tanaka A, Kunikata T, Hirata T, Kato S, Takeuchi K. Inducible types of cyclooxygenase and nitric oxide synthase in adaptive cytoprotection in rat stomachs. J Physiol Paris 1999; 93: 405-12.
74. Ehrlich K, Plate S, Stroff T, Gretzer B, Respondek M, Peskar BM. Peptidergic and cholinergic neurons and mediators in peptone-induced gastroprotection: role of cyclooxygenase-2. Am J Physiol 1998; 274: G955-64.
75. Brzozowski T, Konturek PC, Konturek SJ, et al. Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. Eur J Pharmacol 1999; 385: 47-61.
76. Maricic N, Ehrlich K, Gretzer B, Schuligoi R, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach. Br J Pharmacol 1999; 128: 1659-66.
77. Laudanno OM, Cesolari JA, Esnarriaga J, et al. Gastrointestinal damage induced by celecoxib and rofecoxib in rats. Dig Dis Sci 2001; 46: 779-84.
78. Berenguer B, Alarcon de la Lastra C, Moreno FJ, Martin MJ. Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors. Eur J Pharmacol 2002; 442: 125-35.
79. Kato S, Ogawa Y, Kanatsu K, et al. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 2002; 303: 503-9.
80. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
81. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
82. Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal antiinflammatory drug or a cyclooxygenase-2- selective inhibitor. Aliment Pharmacol Ther 2006; 23: 1489-98.
83. Henry D, McGettigan P. Selective COX-2 inhibitors: a promise unfulfilled? Gastroenterology 2007; 132: 790-4.
84. Whittle BJR. Mechanisms underlying intestinal injury induced by antiinflammatory COX inhibitors. Eur J Pharmacol 2004; 500: 427-39.
85. Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005; 21: 169-75.
86. Thiéfin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72: 286-94.
87. Lanas A, Panes J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003; 9: 2253-66.
88. Reuter BK, Davies NM, Wallace JL. Nonsteroidal antiinflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112: 109-17.
89. Fornai M, Blandizzi C, Colucci R, et al. Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut 2005; 54: 608-16.
90. Schwarz NT, Kalff JC, Turler A, et al. Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology 2001; 121: 1354-71.
91. Kalff JC, Turler A, Schwarz NT, et al. Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann Surg 2003; 237: 301-15.
92. Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ. Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 2001; 48: 468-72.
93. Sigthtorsson G, Simpson RJ, Walley M, et al. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-23.
94. Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal antiinflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002 ; 303:1248-54.
95. Menozzi A, Pozzoli C, Giovannini E, et al. Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat. Eur J Pharmacol 2006; 552: 143-50.
96. Yokota A, Taniguchi M, Tanaka A, Takeuchi K. Development of intestinal, but not gastric damage caused by a low dose of indomethacin in the presence of rofecoxib. Inflammopharmacology 2005; 13: 209-16.
97. Leite AZ, Sipahi AM, Damiao AO, et al. Effect of a selective nonsteroidal antiinflammatory inhibitor of cyclooxygenase-2 on the small bowel of rats. Braz J Med Biol Res 2004; 373: 333-6.
98. Tibble JA, Sigthorsson G, Foster R, Bjarnason I. Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000; 35: 802-7.
99. Zhang L, Lu YM, Dong XY. Effects and mechanism of the selective COX-2 inhibitor, celecoxib, on rat colitis induced by trinitrobenzensulfonic acid. Chin J Dig Dis 2004; 5: 110-4.
100. Singh VP, Patil CS, Jain NK, Kulkarni SK. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology 2004; 72: 77-84.
101. Shafiq N, Malhotra S, Pandhi P, Nada R. Comparative gastrointestinal toxicity of selective cyclooxygenase (COX-2) inhibitors. Indian J Exp Biol 2005; 43: 614-9.
102. Martín AR, Villegas I, La Casa C, Alarcón de la Lastra C. The cyclooxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 2003; 481: 281-91.
103. Cuzzocrea S, Mazzon E, Serraino I, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 2001; 431: 91-102.
104. Biancone L, Tosti C, Geremia A, et al. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 2004; 19: 755-64.
105. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 352-6.
106. Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal antiinflammatory drugs. Aliment Pharmacol Ther 2006; 24: 751-67.
107. Bouras EP, Burton DD, Camilleri M, Stephens DA, Thomforde GM. Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroentenl Motil 2004; 16: 729-35.
108. Rainsford KD. Aspirin and related drugs. Taylor & Francis, London, 2004.
109. Wallace JL, McKnight GW, Keenan CM, Byles NI, MacNaughton WK. Effects of leukotrienes on susceptibility of the rat stomach to damage and investigation of the mechanism of action. Gastroenterology 1990; 98: 1178-86.
110. Gyomber E, Vattay P, Szabo S, Rainsford KD. Effect of lipoxygenase inhibitors and leukotriene antagonists on acute and chronic gastric haemorrhagic mucosal lesions in ulcer models in the rat. J Gastroenterol Hepatol 1996; 11: 922-7.
111. Martel-Pelletier JM, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal antiinflammatory drugs. Ann Rheum Dis 2003; 62: 501-9.
112. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gastric mucosal leukotriene B4 synthesis in patients taking non-steroidal antiinflammatory drugs. Gut 1993; 34: 742-7.
113. Bias P, Buchner A, Klesser B, Laufer S. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004; 99: 611-8.
114. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984; 81: 5335-9.
115. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414-20.
116. Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NOreleasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003; 100: 10937-41.
117. Cirino G. Nitric oxide releasing drugs: from bench to bedside. Dig Liver Dis 2003; 35: S2-8.
118. Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal antiinflammatory and related nitric oxide-donating drugs. Br J Pharmacol 2002; 137: 295-310.
119. Fiorucci S, Distrutti E. Cyclo-oxygenase (COX) inhibiting nitric oxide donating (CINODs) drugs: a review of their current status. Curr Top Med Chem 2007; 7: 277-82.
120. Lopez-Belmonte J, Whittle BJ, Moncada S. The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 1993; 108: 73-8.
121. Barrachina MD, Calatayud S, Canet A. Transdermal nitroglycerin prevents nonsteroidal antiinflammatory drug gastropathy. Eur J Pharmacol 1995; 281: R3-4.
122. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9.
123. Davies NM, Roseth AG, Appleyard CB, et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and antiinflammatory effects. Aliment Pharmacol Ther 1997; 11: 69-79.
124. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal antiinflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-30.
125. Ukawa H, Yamakuni H, Kato S, Takeuchi K. Effects of cyclooxygenase-2 selective and nitric oxide-releasing non-steroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach. Dig Dis Sci 1998; 43: 2003-11.
126. Fiorucci S, Di Lorenzo A, Renga B, Farneti S, Morelli A, Cirino G. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2- naphthaleneacetic acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J Pharmacol Exp Ther 2004; 311: 1264-71.
127. Burgaud JL, Ongini E, Del Soldato P. Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents. Ann NY Acad Sci 2002; 962: 360-71.
128. Fiorucci S, Santucci L, Gresele, P, Faccino, RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003; 124: 600-7.
129. Hawkey CJ, Jones JI, Atherton CT, et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003; 52: 1537-42.
130. Jonzon B, Bjarnason I, Hawkey C, et al. The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology 2003; 11: 437-44.
131. Hill M, Sindet-Pederson S, Seymour RA, et al. Analgesic effects of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double blind, placebo-controlled studies. Clin Ther 2006; 28: 1279-95.
132. Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenicity of nitric oxide-releasing indomethacin, NCX-530 in rats. Aliment Pharmacol Ther 2001; 15: 257-67.
133. Chegaev K, Lazzarato L, Tosco P, et al. NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties. J Med Chem 2007; 50: 1449-57.
134. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006; 20: 2118-20.